IP Library Granted Patent US 12,698,254
Granted Patent B2
US 12,698,254 · App. 18/635,809 · Granted Aug 4, 2026

Crystalline solids of 3-palmitoyl-amido-1,2-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane and methods of making and using the same

Inventor: Jennifer E. Albaneze-Walker (Foster City, CA)
Assignee: Geron Corporation
C07C233/18B01D9/0031B01D2009/0086C07B2200/13C07C231/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,698,254
App. No.
18/635,809
Filed
Apr 15, 2024
Granted
Aug 4, 2026
Kind
B2
Art Unit
1691
USPC
514/625
Abstract

Aspects of the disclosure include crystalline solids of 3-palmitoyl-amido-1,2-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane. Methods for preparing the crystalline solids of 3-palmitoyl-amido-1,2-propanediol and single crystals of 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane are also provided. Methods for preparing a 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane from a crystalline solid of 3-palmitoyl-amido-1,2-propanediol are also described.

Claims (26)

1 . A crystalline solid of a compound of Formula II

wherein DMTr is dimethoxytriphenylmethyl;

each unit cell in the crystalline solid comprises conformer A and conformer B of the compound of Formula II; and conformer A has the atomic coordinates and equivalent isotropic displacement parameters:

O1A

0.8579(3)

0.7210(3)

0.75600(12)

0.0408(9)

N1A

0.0410(5)

0.8405(4)

0.75844(15)

0.0504(13).

2 . The crystalline solid of claim 1 , wherein conformer B has the atomic coordinates and equivalent isotropic displacement parameters:

O1B

0.3551(4)

0.8951(3)

0.74538(15)

0.0585(12)

N1B

0.5490(4)

0.7896(3)

0.76518(12)

0.0331(9).

3 . The crystalline solid of claim 1 , wherein conformer A has the atomic coordinates and equivalent isotropic displacement parameters set forth in Table 2.

4 . The crystalline solid of claim 1 , wherein conformer B has the atomic coordinates and equivalent isotropic displacement parameters set forth in Table 2.

Assignments (4)
PATENT SECURITY AGREEMENT Recorded Nov 12, 2024
From: GERON CORPORATION
To: BIOPHARMA CREDIT PLC [COLLATERAL AGENT]
Reel/Frame 069341/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2024
From: JANSSEN BIOTECH, INC.
To: GERON CORPORATION
Reel/Frame 067961/0577 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2024
From: ALBANEZE-WALKER, JENNIFER E.
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 068281/0755 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2024
From: JANSSEN PHARMACEUTICA NV
To: JANSSEN BIOTECH, INC.
Reel/Frame 068283/0181 →
Continuity (3)
Division 17079204 · Oct 23, 2020
Provisional Application 62926810 · Oct 28, 2019
Related Publication 20240360074A1 · Oct 31, 2024
References Cited (34)
US 9266816B2 · Shrawat et al. · 2016 [cited by applicant]
US 9657296B2 · Gryaznov et al. · 2017 [cited by applicant]
US 20060069156A1 · Darteil et al. · 2006 [cited by applicant]
US 20060121583A1 · Lassalle et al. · 2006 [cited by applicant]
US 20060154984A1 · Darteil et al. · 2006 [cited by applicant]
US 20090048427A1 · Hedgpeth et al. · 2009 [cited by applicant]
US 20110286937A1 · Kiso et al. · 2011 [cited by applicant]
US 20120329858A1 · Gryaznov · 2012 [cited by examiner]
US 20150337314A1 · Premchandran · 2015 [cited by applicant]
US 20170130225A1 · Gryaznov et al. · 2017 [cited by applicant]
CN 106459134 · 2017 [cited by applicant]
EP 1644318 · 2008 [cited by applicant]
KR 101809614 · 2017 [cited by applicant]
KR 101861785 · 2018 [cited by applicant]
WO WO9518820 · 1995 [cited by applicant]
WO WO1996032496A2 · 1996 [cited by applicant]
WO WO2005023994 · 2005 [cited by applicant]
WO WO2019011829A1 · 2019 [cited by applicant]
Gehlert et al., (1998) “Relating Domain Morphology and Lattice Structure in Monolayers of Glycerol Amide Lipids”, Langmuir, 14(8): 2112-2118. [cited by applicant]
Pubchem-CID: 11002017 Create Date: Oct. 26, 2006 (Oct. 26, 2006) pp. 1-11; p. 2. [cited by applicant]
Ouyang et al., “Structure—Activity Relationship for Enhancement of Paracellular Permeability across Cacom2 Cell Monolayers by 3mA1kylamidom2malkoxypropylphosphocholines” (2002) J. Med. Chem., 45: 2857-2866. [cited by applicant]
Xu et al. (2016) “Quantitative chemical analysis”, Nankai University Press, 2 pages. [cited by applicant]
Legrand et al., (2016) “Hybrid Fluorinated and Hydrogenated Double-Chain Surfactants for Handling Membrane Proteins”, The Journal of Organic Chemistry, 81(2):681-688. [cited by applicant]
Liang, (2007) “Screening Polymorphic Forms of Drug substances by Using Generalized Crystallization Techniques”, National Taipei University of Technology, Chemical Engineering, pp. 1-149. [cited by applicant]
Asahara, (1985) “Handbook of solvent”, Kodansha Ltd., p. 47-51. [cited by applicant]
Hirayama, (2008) “Handbook for preparation of organic compound crystal-principle and know how”, pp. 57-84. [cited by applicant]
Maruzen, (2003) “technique of chemical synthesis”, The Chemical Society of Japan, Handbook of chemistry, applied chemistry, 6(4):178. [cited by applicant]
Matsuoka, (2010) “Base & Application of Polymorphic Crystals”, popular edition, 1st printing, CMC Publishing Co., Ltd., pp. 105-117, 181-191. [cited by applicant]
Marx et.al., (1988) “Synthesis and evaluation of neoplastic cell growth inhibition of 1-N-alkylamide analogs of glycero-3-phosphocholine”, Journal of Medicinal Chemistry, 31:858-863. [cited by applicant]
Takata, (2007) “API form screening and selection in drug discovery stage”, Pharm Stage, 6(10):20-25. [cited by applicant]
Wermuth, (1999) “The Practice of Medicinal Chemistry”, Technomics, Inc., pp. 347-365, 452-453. [cited by applicant]
Strain, Jacob; (2025) “X-Ray Diffraction (XRD)—XRD Principle, XRD Analysis and Applications” Technology Networks; 1-24. [cited by applicant]
Haleblian and McCrone, (1969) “Pharmaceutical Applications of Polymorphism”, Journal of Pharmaceutical Sciences, 58(8), 911-929. [cited by applicant]
[cited by applicant]